Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2018

01-02-2018 | Gastrointestinal Oncology

Correlation Between Biomarker Candidate Proteins with the Effect of Neoadjuvant Chemoradiation Therapy on Esophageal Squamous Cell Carcinoma

Authors: Masahiro Noda, MD, Hiroshi Okumura, MD, PhD, Yasuto Uchikado, MD, PhD, Itaru Omoto, MD, PhD, Ken Sasaki, MD, PhD, Yoshiaki Kita, MD, PhD, Shinichiro Mori, MD, PhD, Tetsuhiro Owaki, MD, PhD, Takaaki Arigami, MD, PhD, Yoshikazu Uenosono, MD, PhD, Akihiro Nakajo, MD, PhD, Yuko Kijima, MD, PhD, Sumiya Ishigami, MD, PhD, Kosei Maemura, MD, PhD, Shoji Natsugoe, MD, PhD

Published in: Annals of Surgical Oncology | Issue 2/2018

Login to get access

Abstract

Background

While chemoradiation therapy (CRT) is one of the most useful treatments for esophageal squamous cell carcinoma (ESCC), it is important to predict response prior to treatment by using markers because some patients respond well and others do not.

Methods

Fifty-nine patients with ESCC were treated with neoadjuvant CRT at the Kagoshima University Hospital. The expression of seven types of biomarker candidate proteins in biopsy specimens of untreated primary tumors was evaluated to determine whether it correlated with response and prognosis.

Results

The positive expression rates were 47% for p53, 83% for CDC25B, 68% for 14-3-3sigma, 76% for p53R2, 75% for ERCC1, 32% for Gli-1, and 54% for Nrf2. In terms of histological response, tumor grade of the 59 patients was 48.8% for grade 1 as the non-responder, 29.2% for grade 2, and 22.0% for grade 3 as the responder. CRT was significantly effective in p53(−), p53R2(−), ERCC1(−), and Nrf2(−) tumors, while p53(−), p53R2(−), and ERCC1(−) were factors independently correlated with effective histological response. Their combined expression of two or three negative expressions had 100% effective response and was a significant prognostic factor.

Conclusion

Our results suggest that two or three negative expressions of p53, p53R2, and ERCC1 in biopsy specimens of primary tumors were associated with a favorable response to CRT for ESCC. Assessment of tumor suppressor and DNA repair protein expressions in biopsy specimens may be useful for the potential utility of CRT therapy for patients with ESCC prior to treatment.
Appendix
Available only for authorised users
Literature
1.
2.
Natsugoe S, Matsumoto M, Okumura H, et al. Clinical course and outcome after esophagectomy with three-field lymphadenectomy in esophageal cancer. Langenbecks Arch Surg. 2010;395:341–46.CrossRefPubMed
3.
Tachimori Y, Ozawa S, Numasaki H, et al. Efficacy of lymph node dissection by node zones according to tumor location for esophageal squamous cell carcinoma. Esophagus. 2016;13:1–7.CrossRefPubMed
4.
Natsugoe S, Ikeda M, Baba M, et al. Long-term survivors of advanced esophageal cancer without surgical treatment: a multicenter questionnaire survey in Kyushu, Japan. Dis Esophagus. 2003;16:239–42.CrossRefPubMed
5.
Okumura H, Uchikado Y, Matsumoto M, et al. Prognostic factors in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiation therapy. Int J Clin Oncol. 2013;8:329–34.CrossRef
6.
Okumura H, Uchikado Y, Omoto I, et al. The usefulness of neoadjuvant chemoradiation therapy for locally advanced esophageal cancer with multiple lymph-node metastases. Ann Surg Oncol. 2014;21:2845–49.CrossRefPubMed
7.
Okumura H, Uchikado Y, Setoyama T, et al. Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy. Surg Today. 2014;44:421–28.CrossRefPubMed
8.
Sobin LH, Wittekind C. International Union Against Cancer (UICC) TNM classification of malignant tumours, 6th edn. New York: Wiley; 2002.
9.
Japan Esophageal Society. Japanese Classification of Esophageal Cancer, 4th edn, part I. Esophagus. 2009;6:1–25.
10.
Japan Esophageal Society: Japanese Classification of Esophageal Cancer, 4th edn, parts II and III. Esophagus. 2009;6:71–94.
11.
Okumura H, Natsugoe S, Yokomakura N, et al. Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res. 2006;12:3740–45.CrossRefPubMed
12.
Miyata H, Doki Y, Shiozaki H, et al. CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin Cancer Res. 2000;6:4859–65.PubMed
13.
Okumura H, Kita Y, Yokomakura N, et al. Nuclear expression of 14-3-3 sigma is related to prognosis in patients with esophageal squamous cell carcinoma. Anticancer Res. 2010;30:5175–79.PubMed
14.
Kim MK, Cho KJ, Kwon GY, et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer. 2008;44:54–60.CrossRefPubMed
15.
Yoshikawa R, Nakano Y, Tao L, et al. Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy. Br J Cancer. 2008;98:1670–74.CrossRefPubMedPubMedCentral
16.
Kawasaki Y, Okumura H, Uchikado Y, et al. Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma. Ann Surg Oncol. 2014;21:2347–52.CrossRefPubMed
17.
Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266: 807–10.CrossRefPubMed
18.
Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 1994;370:220–23.CrossRefPubMed
19.
Wagata T, Shibagaki I, Imamura M, et al. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res. 1993;53:846–50.PubMed
20.
Tanaka H, Arakawa H, Yamaguchi T, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000;404:42–49.CrossRefPubMed
21.
Yamaguchi T, Matsuda K, Sagiya Y, et al. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res. 2001;61: 8256–62.PubMed
22.
Okumura H, Natsugoe S, Matsumoto M, et al. The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma. Br J Cancer. 2005;92:284–89.CrossRefPubMedPubMedCentral
23.
Kwon HC, Roh M, Oh SY, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007;18:504–09.CrossRefPubMed
24.
Joshi MB, Shirota Y, Danenberg KD, et al. High gene expression of TS1, GSTP1, and ERCC1are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2005;11:2215–21.CrossRefPubMed
25.
Kim MK, Cho KJ, Kwon GY, et al. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res. 2008;14:4225–23.CrossRefPubMed
Metadata
Title
Correlation Between Biomarker Candidate Proteins with the Effect of Neoadjuvant Chemoradiation Therapy on Esophageal Squamous Cell Carcinoma
Authors
Masahiro Noda, MD
Hiroshi Okumura, MD, PhD
Yasuto Uchikado, MD, PhD
Itaru Omoto, MD, PhD
Ken Sasaki, MD, PhD
Yoshiaki Kita, MD, PhD
Shinichiro Mori, MD, PhD
Tetsuhiro Owaki, MD, PhD
Takaaki Arigami, MD, PhD
Yoshikazu Uenosono, MD, PhD
Akihiro Nakajo, MD, PhD
Yuko Kijima, MD, PhD
Sumiya Ishigami, MD, PhD
Kosei Maemura, MD, PhD
Shoji Natsugoe, MD, PhD
Publication date
01-02-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 2/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6271-y

Other articles of this Issue 2/2018

Annals of Surgical Oncology 2/2018 Go to the issue

Breast Oncology

Molecular Genomic Testing for Breast Cancer: Utility for Surgeons

Colorectal Cancer

Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study

Breast Oncology

How Low Can We Go—and Should We? Risk Reduction for Minimal-Volume DCIS

Melanomas

Use of a Purse-String Suture to Reduce Skin Graft Requirements

Gastrointestinal Oncology

A Novel Preoperative Skeletal Muscle Measure as a Predictor of Postoperative Complications, Long-Term Survival and Tumor Recurrence for Patients with Gastric Cancer After Radical Gastrectomy

Urologic Oncology

Perioperative Complications and Mortality in Patients with Urothelial Carcinoma and End-Stage Renal Disease Undergoing One-Stage Complete Urinary Tract Extirpation